Health Technology Clinical Committee
Date: September 21, 2012  
Time: 8:00 am – 12:00 pm  
Location: SeaTac Airport Conference Center  
Adopted: November 16, 2012

Meeting materials and transcript are available on the HTA website at:
http://www.hta.hca.wa.gov/past_materials.html

HTCC MINUTES

Members Present: C. Craig Blackmore MD, MPH; Marie-Annette Brown PhD, RN; Joann Elmore, MD MPH; David McCulloch, MD; Carson E. Odegard DC, MPH; Richard C. Phillips MD, MS, MPH; Seth Schwartz MD, MPH; Michelle Simon PhD, ND; Michael Souter MB, Ch-B, DA, Christopher Standaert, MD; Kevin Walsh MD

Members Absent: None

HTCC FORMAL ACTION

1. Call to Order: Dr. Blackmore, Chair, called the meeting to order. Sufficient members were present to constitute a quorum.

2. May 18 Meeting Minutes: Chair referred members to the draft minutes; motion to approve and second, and adopted by the committee.

   Action: Ten committee members approved the March 16, 2012 meeting minutes. One member abstained.

3. Upper Endoscopy with GERD Symptoms Draft Findings & Decision: Chair referred members to the draft findings and decision and called for further discussion or objection.

   The Upper Endoscopy with GERD Symptoms Draft Findings & Decision was approved and adopted by the committee.

   Action: Ten committee members approved the Upper Endoscopy with GERD Symptoms Draft Findings & Decision document. One member abstained.

4. Robotic Assisted Surgery Draft Findings & Decision: Chair referred members to the draft findings and decision and called for further discussion or objection.

   The Robotic Assisted Surgery Draft Findings & Decision was approved and adopted by the committee.

   Action: Ten committee members approved the Robotic Assisted Surgery Draft Findings & Decision document. One member abstained.
5. **Intensity Modulated Radiation Therapy:**

**Scheduled and Open Public Comment:**

The Chair called for public comments.

- **Scheduled Public Comments:** Seven stakeholders scheduled time for public comments.

- **Open Public Comments:**
  - John Rieke, MD, American Society of Radiation Oncology, Medical Director, MultiCare Regional Cancer Center
  - George Laramore, MD, University of Washington Medical Center, Seattle Cancer Care Alliance
  - Kenneth Russell, MD, University of Washington Medical Center, Seattle Cancer Care Alliance
  - Jason Rockhill, MD, University of Washington Medical Center, Seattle Cancer Care Alliance
  - Ralph Ermoian, MD, University of Washington Medical Center, Seattle Cancer Care Alliance
  - Edward Kim, MD, University of Washington Medical Center, Seattle Cancer Care Alliance
  - Joseph Hartman, MD, RadiantCare Radiation Oncology LLC

- **Written public comments:** One stakeholder provided written comment to the committee.
  - Huong Pham, MD, Section Head, Radiation Oncology, Virginia Mason Medical Center

**Agency Utilization and Outcomes:**

Jeff Thompson MD, MPH Chief Medical Officer, Health Care Authority, presented the state agency utilization rates for Intensity Modulated Radiation Therapy to the committee. The full presentation is published with [September 21 meeting materials](#).

**Vendor Report and HTCC Q & A:**

The Chair introduced the clinical expert, Martin Fuss MD, professor and Vice Chair, Director Program in Image-guided Radiation Therapy, Department of Radiation Medicine, Oregon Health & Science University.

Edgar E. Clark MD, MHA of the Center for Evidence-based Policy, Oregon Health and Science University, presented the evidence review addressing Intensity Modulated Radiation Therapy. The full presentation is published with [September 21 meeting materials](#).

**Committee Discussion and Decision**

The HTCC reviewed and considered the Intensity Modulated Radiation Therapy technology assessment report and information provided by the state agencies. They also heard comments from
the evidence reviewer, the clinical expert, the public, and agency medical directors. The committee considered all the evidence and gave greatest weight to the evidence it determined, based on objective factors, to be the most valid and reliable.

<table>
<thead>
<tr>
<th>HTCC Committee Coverage Determination Vote</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>Not covered</td>
</tr>
<tr>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>Intensity Modulated Radiation Therapy</td>
</tr>
</tbody>
</table>

- **Discussion:** The Chair called for discussion of conditions of coverage for Intensity Modulated Radiation Therapy following the majority voting for coverage. The following conditions were discussed and approved by a majority of the clinical committee:

- **Limitations of Coverage:** Intensity Modulated Radiation Therapy is a covered benefit for the following conditions:
  - Head and neck cancers;
  - Prostate cancer;
  - To spare adjacent critical structures to prevent toxicities within expected life span; or
  - Undergoing treatment in the context of evidence collection /submission of outcome data (e.g., registry, observational study).

The committee checked for availability of a Medicare decision. The Centers for Medicare and Medicaid Services have no published national coverage determinations (NCD) for Intensity Modulated Radiation Therapy.

6. **The Chair called for further comments. Meeting adjourned.**